ACETAZONE FORTE C8 8 MG
CODEINE PHOSPHATE : 8 MG ACETAMINOPHEN : 300 MG CHLORZOXAZONE : 250 MG · DIN 00834319 · TEVA CANADA LIMITED
Health Canada status: CANCELLED POST MARKET
What is ACETAZONE FORTE C8?
ACETAZONE FORTE C8 8 MG contains CODEINE PHOSPHATE : 8 MG ACETAMINOPHEN : 300 MG CHLORZOXAZONE : 250 MG. It is listed in the Health Canada Drug Product Database under DIN 00834319, held by TEVA CANADA LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 30-Nov-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 00834319 |
|---|---|
| Brand name | ACETAZONE FORTE C8 |
| Generic / active ingredient | CODEINE PHOSPHATE : 8 MG ACETAMINOPHEN : 300 MG CHLORZOXAZONE : 250 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 8 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | NARCOTICS (CDSA I) |
| ATC code | M03BB53 CHLORZOXAZONE, COMBINATIONS EXCL PSYCHOLEPTICS |
| AHFS class | 12:20.04 ; 28:08.92 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 30-Nov-2021 |
| Original market date | 1991-12-31 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code M03BB53 CHLORZOXAZONE, COMBINATIONS EXCL PSYCHOLEPTICS. 0 of 8 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACETAZONE FORTE | 300 MG | TABLET | TEVA CANADA LIMITED | CANCELLED POST MARKET | DIN 00834300 |
| BACK-AID FORTE - TAB | 250 MG | TABLET | ROUGIER PHARMA DIVISION OF RATIOPHARM INC | CANCELLED POST MARKET | DIN 02171287 |
| EXTRA STRENGTH TYLENOL ACHES AND STRAINS | 250 MG | TABLET | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | CANCELLED POST MARKET | DIN 02155214 |
| GIN PAIN PILLS - TAB | 250 MG | TABLET | STELLA PHARMACEUTICAL CANADA INC. | CANCELLED POST MARKET | DIN 02212870 |
| PARAFON FORTE | 300 MG | TABLET | MCNEIL PHARMACEUTICAL, DIVISION OF ORTHO-MCNEIL INC. | CANCELLED POST MARKET | DIN 00132519 |
| PARAFON FORTE C8 W CODEINE TAB | 300 MG | TABLET | MCNEIL PHARMACEUTICAL, DIVISION OF ORTHO-MCNEIL INC. | CANCELLED POST MARKET | DIN 00614920 |
| PARAFON FORTE TABLETS | 300 MG | TABLET | JOHNSON & JOHNSON - MERCK CONSUMER PHARMACEUTICALS OF CANADA | CANCELLED POST MARKET | DIN 02229946 |
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.